Brendan P. Eckelman, Chief Scientific Officer at Inhibrx, Inc. (INBX), sold 2,195,553 shares at $34.30 ($67.2M) on 2024-05-28, disclosed to the SEC on 2024-05-30.
Open-market sale of $67.2M INBX by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $34.30 | 300,000 | $10.3M | 15.3% |
| 2 | $30.00 | 160,000 | $4.8M | 7.1% |
| 3 | $30.00 | 1,735,553 | $52.1M | 77.5% |
| Total | $30.59 avg | 2,195,553 | $67.2M | 100% |
| Filing → |
| INBX | SELL | 2022-11-02 | $2.7M | — | Filing → |
| INBX | SELL | 2022-10-05 | $2.2M | — | Filing → |
| INBX | SELL | 2022-09-07 | $1.2M | — | Filing → |